Holly Quasny

Long-term steroid-sparing effect of belimumab in systemic lupus erythematosus: Post hoc pooled analysis of OBSErve multi-country cohort data

Daniel Moldaver, Seth Anderson, Marguerite G. Bracher, Holly Quasny et autres

ObjectiveBelimumab, a B-cell modulator, targets the central immunopathogenic pathway in systemic lupus erythematosus (SLE) by selectively inhibiting B lymphocyte stimulator (BLyS) and reducing the autoreactive B cells that drive disease activity. Its effectiveness in reducing disease activity and its steroid-sparing potential have …

fr, gb (code pays fourni par la source)

Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort

Jacob N. Hunnicutt, Mary Elizabeth Jones, Anna A. Richards, Holly Quasny et autres

OBJECTIVE: One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low disease activity (LDA) states and organ damage rate. METHODS: This retrospective real-world …

us, gb (code pays fourni par la source)

Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials

Ioannis Parodis, Julius Lindblom, Roger A. Levy, Margherita Zen et autres

se, us, it, au, ae, gb, nl (code pays fourni par la source)

POS0530 BELIMUMAB REDUCES DISEASE FLARES VERSUS PLACEBO IN ADULTS WITH EARLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS

Marta Mosca, Karen Costenbader, Joan T. Merrill, Holly Quasny et autres

it, us, jp, nl (code pays fourni par la source)

O1 Impact of intravenous belimumab treatment on steroid use and disease activity in patients with Systemic Lupus Erythematosus (SLE) in the US in clinical practice: 24-month results from the OBSErve study

Daniel Moldaver, Seth Anderson, Marguerite G. Bracher, Roger A. Levy et autres

Objective Oral glucocorticoids (OGCs), antimalarials and immunosuppressants are the mainstay of SLE treatment; however, cumulative OGC use is associated with increased risk of organ damage. Thus, OGC dose reduction or complete withdrawal with the attainment of remission (measured by the Definition Of …

us, gb (code pays fourni par la source)

Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo‐controlled trial in North East Asia

Chang‐Hee Suh, Yoon‐Hee Lee, Sang‐Bae Yoo, Holly Quasny et autres

AIM: This post hoc analysis evaluated the efficacy and safety of intravenous belimumab 10 mg/kg in the South Korean subgroup of patients with systemic lupus erythematosus (SLE) enrolled in the North East Asia (NEA) study (GSK Study BEL113750; NCT01345253). METHODS: NEA was …

kr, us (code pays fourni par la source)

Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study

He Xin, Emily Lloyd, Selin Cooper, Lei Li et autres

OBJECTIVES: This study aimed to describe the healthcare resource utilization (HCRU) and healthcare costs associated with systemic lupus erythematosus (SLE) management in China from the patient's and the payer's perspective. METHODS: HCRU and medical costs (2017 US dollar [USD]) between January 1 …

cn, gb, us (code pays fourni par la source)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study

Jacob N. Hunnicutt, Jolyon Fairburn-Beech, Mary Elizabeth Georgiou, Anna A. Richards et autres

OBJECTIVE: To characterise disease control and remission in patients with SLE receiving belimumab for up to 12 months in the real world. METHODS: This post hoc analysis (GSK Study 213502) used data from the US evaluation Of use of Belimumab in clinical …

us, gb (code pays fourni par la source)

Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses

Jie Zheng, Jieruo Gu, Yin Su, Yang Li et autres

OBJECTIVES: To assess belimumab efficacy in patients from North East Asia (NEA) with systemic lupus erythematosus (SLE) in baseline demographic/disease characteristic subgroups. METHODS: This analysis of patient subgroups from BLISS-NEA (GSK Study 113750; NCT01345253) studied adults with SLE randomized to belimumab (10 …

cn, us (code pays fourni par la source)

Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data

Daniel J. Wallace, Tatsuya Atsumi, Mark Daniels, Anne E. Hammer et autres

OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that affects multiple organ systems. Belimumab, a targeted human monoclonal antibody, binds to and inhibits soluble B-lymphocyte stimulator. The safety and efficacy of belimumab has consistently been demonstrated in multiple clinical trials …

us, jp, de, cn (code pays fourni par la source)

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports

Michelle Petri, Helain J. Landy, Megan E. B. Clowse, Kim Gemzoe et autres

OBJECTIVE: Describe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab. METHODS: Data collected from belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing/spontaneous reports up to 8 March 2020 were described. …

us, gb, it, ae (code pays fourni par la source)

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT

Ken‐ei Sada, Noriaki Kurita, Hisashi Noma, Taizo Matsuki et autres

INTRODUCTION: Lupus nephritis (LN) is more prevalent in patients with SLE of Asian ethnicity than in Caucasian patients. Belimumab became available in Japan in 2017 to treat patients with SLE, including those with LN. In the BLISS-LN trial (NCT01639339), belimumab showed a …

jp, us, gb (code pays fourni par la source)